Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio

Contributed by: PR Newswire

Images

PR Newswire associated0
PR Newswire associated1

Tags

Jazz-Pharma-Chimerix

More Like This

PR Newswire associated0

Jazz Pharmaceuticals Completes Acquisition of Chimerix

PR Newswire associated0

Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program

PR Newswire associated0

Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance

PR Newswire associated0

Jazz Pharmaceuticals Announces Private Offering of $850 Million of Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases

PR Newswire associated0

Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 3.125% Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases

PR Newswire associated0

Jazz Pharmaceuticals Announces Third Quarter 2023 Financial Results and Updates Financial Guidance

PR Newswire associated0

Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024

PR Newswire associated0

Jazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance